NCT05806814 2026-03-05
OU-SCC-EXCITE
University of Oklahoma
Phase 1 Recruiting
Clinical Trials
9 trialsNCT05670106 2026-02-13
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
Novartis
Phase 2 Active not recruiting
NCT06126731 2025-11-24
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT06134232 2025-08-27
ProvONE
Dendreon
Phase 2 Recruiting
NCT05658003 2025-08-22
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis
Phase 2 Active not recruiting
NCT04015622 2025-08-20
PROTRACT
British Columbia Cancer Agency
Phase 2 Active not recruiting
NCT04691804 2024-12-31
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT03712930 2021-11-17
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
BeiGene
Phase 2 Terminated
NCT03074032 2017-07-11
Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Avionco LLC
Phase 1 Completed